Androgen substitution with testosterone undecanoate in survivors of bilateral testicular cancer requires individually-adjusted injection intervals

BJU International

Volumn 107, Issue 7, 2011, Pages 1080-1087

  Brabrand, Sigmund ^a   Fosså, Sophie D ^b   Cvancarova, Milada ^b   Lehne, Gustav ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

androgen substitution; germ cell testicular cancer; hypogonadism; testosterone undecanoate

Indexed keywords

ANDROGEN; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ADULT; AGING MALES SYMPTOMS SCALE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURVIVOR; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INDIVIDUALIZATION; MALE; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; ORCHIECTOMY; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SIDE EFFECT; STEADY STATE; TESTIS CANCER; TESTOSTERONE BLOOD LEVEL;

ADULT; ANDROGENS; EPIDEMIOLOGIC METHODS; HUMANS; HYPOGONADISM; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; TESTICULAR NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 79953198275     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09649.x     Document Type: Article

References (31)

1. Dearnaley D, Huddart R, Horwich A,. Regular review: managing testicular cancer. BMJ 2001; 322: 1583-8 (Pubitemid 32592294)
2. Dieckmann KP, Loy V, Büttner P,. Prevalence of bilateral testicular germ cell tumours and early detection based on contralateral testicular intra-epithelial neoplasia. Br J Urol 1993; 71: 340-5 (Pubitemid 23102262)
3. Hoff Wanders E, Foss SD, Tretli S,. Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 norwegian male patients. Eur J Cancer 1997; 33: 244-52 (Pubitemid 27117722)
4. Gooren LJGB, Mathijs CM,. Androgen replacement therapy: present and future. Drugs 2004; 64: 1861-91 (Review). (Pubitemid 39243569)
5. Schubert M, Minnemann T, Hubler D, et al,. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89: 5429-34 (Pubitemid 39518421)
6. Behre H, Abshagen K, Oettel M, Hubler D, Nieschlag E,. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999; 140: 414-9 (Pubitemid 29254007)
7. Nieschlag E, Büchter D, Eckardstein S, Abshagen K, Simoni M, Behre HM,. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol 1999; 51: 757-63 (Pubitemid 30050826)
8. von Eckardstein S, Nieschlag E,. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 2002; 23: 419-25 (Pubitemid 34297331)
9. Vermeulen A, Verdonck L, Kaufman JM,. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72 (Pubitemid 30645223)
10. Daig I, Heinemann L, Kim S, et al,. The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 2003; 1: 77
11. Moore C, Huebler D, Zimmermann T, Heinemann LAJ, Saad F, Thai DM,. The Aging Males' Symptoms Scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46: 80-7 (Pubitemid 38748514)
12. Heinemann LAJ, Saad F, Heinemann K, Thai DM,. Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency? Aging Male 2004; 7: 211-8 (Pubitemid 39315125)
13. Jacobsen KD, Foss SD, BjÃro TP, Aass N, Heilo A, Stenwig AE,. Gonadal function and fertility in patients with bilateral testicular germ cell malignancy. Eur Urol 2002; 42: 229-38 (Pubitemid 35024233)
14. Jacobsen KD, Theodorsen L, Fossa SD,. Spermatogenesis after unilateral orchiectomy for testicular cancer in patients following surveillance policy. J Urol 2001; 165: 93-6
15. Maréchal J-D, Kemp CA, Roberts GCK, Paine MJI, Wolf CR, Sutcliffe MJ,. Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions. Br J Pharmacol 2008; 153: S82-S89 (Pubitemid 351340994)
16. Zhang Y-Y, Yang L,. Interactions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications. Expert Opin Drug Metab Toxicol 2009; 5: 621-9
17. Lewis DF,. 57 varieties: the human cytochromes P450. Pharmacogenomics 2004; 5: 305-18 (Pubitemid 38499969)
18. Novelli G, Margiotti K, Chiocca AM, Spera E, Micali F, Reichardt JK,. Pharmacogenetics of human androgens and prostate cancer-an update. Pharmacogenomics 2004; 5: 283-94 (Pubitemid 38499967)
19. Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W,. A new 'aging males' symptoms' rating scale. Aging Male 1999; 2: 105-14 (Pubitemid 29411279)
20. Heinemann L, Saad F, Zimmermann T, et al,. The Aging Males' Symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes 2003; 1: 15
21. Legros J-J, Meuleman EJH, Elbers JMH, et al,. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 2009; 160: 821-31
22. Morley JE, Perry Iii HM, Kevorkian RT, Patrick P,. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006; 53: 424-9
23. Miwa Y, Kaneda T, Yokoyama O,. Correlation between the aging males' symptoms scale and sex steroids, gonadotropins, dehydroepiandrosterone sulfate, and growth hormone levels in ambulatory men. J Sex Med 2006 3: 723-6
24. Kratzik C, Heinemann LAJ, Saad F, Thai DM, Rücklinger E,. Composite screener for androgen deficiency related to the Aging Males' Symptoms scale. Aging Male 2005; 8: 157
25. Tsujimura A, Matsumiya K, Miyagawa Y, et al,. Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int J Impot Res 2004; 17: 259-63
26. T'Sjoen G, Goemaere S, De Meyere M, Kaufman JM,. Perception of males' aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels. Psychoneuroendocrinology 2004; 29: 201-14 (Pubitemid 37357179)
27. Laughlin GA, Barrett-Connor E, Bergstrom J,. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75
28. Yeap BB,. Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res 2008; 21: 24-36
29. Corona G, Mannucci E, Forti G, Maggi M,. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009; 32: 587-98
30. Allan CA, Strauss BJG, Burger HG, Forbes EA, McLachlan RI,. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008; 93: 139-46
31. Saad F, Kamischke A, Yassin A, et al,. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl 2007; 9: 291-7 (Pubitemid 47097283)